LMAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LeMaitre Vascular Inc (LMAT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company's financial performance is impressive, the lack of strong positive trading signals, neutral technical indicators, and hedge fund selling trends suggest waiting for a better entry point.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 49.327, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near a key support level (S1: 112.079), with resistance at 114.543. However, the overall technical indicators do not strongly suggest a buy.
Strong financial performance in Q4 2025, with revenue up 15.68% YoY, net income up 39.32% YoY, EPS up 38.78% YoY, and gross margin up 3.47%. Analysts have raised price targets recently, with some maintaining a Buy or Outperform rating.
Hedge funds are selling heavily, with a 398.42% increase in selling over the last quarter. No recent news or significant insider activity. The stock has a 70% chance of declining over the next month (-5.03%).
In Q4 2025, LeMaitre reported strong growth: revenue increased to $64.45M (+15.68% YoY), net income rose to $15.58M (+39.32% YoY), EPS grew to $0.68 (+38.78% YoY), and gross margin improved to 71.66% (+3.47% YoY).
Recent analyst ratings are mixed. Freedom Capital initiated coverage with a Hold rating and a $113 price target, citing concerns about future price increases. Roth Capital, Barrington, and Citizens raised price targets to $117, $105, and $118, respectively, with Buy or Outperform ratings, citing strong sales growth, margin expansion, and international growth.
